Ebos Group Ltd

EBO: XNZE (NZL)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|.P#LOCK|WtW>SLOCK|hM<jq$qG

Ebos Group Earnings: Shares Undervalued, With Margins Poised to Expand Near-Term

Ebos' interim 2026 underlying EBITDA grew 3% to AUD 300 million. Sales rose 13%, but profitability fell on lower-margin weight-loss drugs and a margin-dilutive New Zealand acquisition. Full-year guidance was reaffirmed, implying second-half underlying EBITDA lifting to roughly AUD 325 million.

Sponsor Center